← 產業報告目錄
Idiopathic Pulmonary Fibrosis Management Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib, Interferon Gammato1b, Others), By Treatment (Oxygen Therapy, Lung Transplant), By Route of Administration, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-26頁數 165報告編號 INSIGHTACE-72997c44d7
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 3,113.5 Mn as of 2023, the global Idiopathic Pulmonary Fibrosis Management Market is poised to climb to USD 3,429.6 Mn by 2031, reflecting a compound annual growth rate of 1.28% over the 2024–2031 period.
At its core, Idiopathic Pulmonary Fibrosis Management pertains to landscape are expandingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, underpinned by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Idiopathic Pulmonary Fibrosis Management Market Snapshot
Chapter 4. Global Idiopathic Pulmonary Fibrosis Management Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Idiopathic Pulmonary Fibrosis Management Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Idiopathic Pulmonary Fibrosis Management Industry Trends
Chapter 5. Idiopathic Pulmonary Fibrosis Management Market Segmentation 1: By Drug Class, Estimates & Trend Analysis
5.1. Market Share by Drug Class, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class:
5.2.1. Pirfenidone
5.2.2. Nintedanib
5.2.3. Interferon Gammato1b
5.2.4. Others
Chapter 6. Idiopathic Pulmonary Fibrosis Management Market Segmentation 2: By Treatment, Estimates & Trend Analysis
6.1. Market Share by Treatment, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatments:
6.2.1. Oxygen Therapy
6.2.2. Lung Transplant
6.2.3. Others
Chapter 7. Idiopathic Pulmonary Fibrosis Management Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:
7.2.1. Oral
7.2.2. Injectable
Chapter 8. Idiopathic Pulmonary Fibrosis Management Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Idiopathic Pulmonary Fibrosis Management Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Idiopathic Pulmonary Fibrosis Management Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.2.3. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.2.4. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.2.5. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.3. Europe
9.3.1. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.3.3. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.3.4. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.3.5. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.4.3. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.4.4. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.4.5. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.5. Latin America
9.5.1. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.5.3. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.5.4. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.5.5. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.6.3. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.6.4. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.6.5. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Boehringer Ingelheim GMBH
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Biogen
10.2.3. Novartis AG
10.2.4. Medicinova Inc
10.2.5. Bristol Myers Squibb Company
10.2.6. Galapagos NV
10.2.7. Hoffmann-La Roche AG
10.2.8. Neopharm Group
10.2.9. Galecto Biotech
10.2.10. Pfizer Inc
10.2.11. Johnson & Johnson Services, Inc
10.2.12. AstraZeneca
10.2.13. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們